It produces significant (>50%) tumour regression in ∼15% of patients with HER2-positive metastatic breast cancer that is refractory to conventional therapy, and in ∼23% of patients when used as first-line therapy (Cobleigh et al, 1999). Here, ERBB2 is linked to neoplasm.